Malvern Instruments Presents Solutions to Characterizing Sub-Micron Protein Aggregates
![](/46/pdcnewsitem/03/34/20/J8OuUgqnau7l0SP.jpg)
In an upcoming webinar on the 26th June, 2014, Malvern Instruments will present new experimental data demonstrating how Archimedes Resonant Mass Measurement (RMM) helps developers meet evolving regulatory challenges facing the biopharmaceutical industry. ‘Protein aggregation — Bridging the sub micron gap’ will explore how the Archimedes system enables formulators to characterize and quantify sub-visible particles within biotherapeutic formulations between 0.1 and10 µm. By accessing this previously challenging size range, the Archimedes allows developers to meet regulatory requirements to monitor aggregate formation throughout the entire product shelf life.
The formation of protein aggregates is a particular concern for biopharmaceuticals requiring parenteral administration because of the potential for increased immunogenicity. As a consequence, there is an expectation from regulatory agencies for developers to monitor levels of sub-visible particles present in therapeutic protein products initially and over the course of the shelf life. Presented by Dr Matthew Brown, Product Technical Specialist — Life Sciences, Malvern Instruments Ltd, the webinar will provide an overview of the challenges involved in characterizing and quantifying these sub-visible species. Dr Brown will demonstrate how innovative Archimedes RMM technology delivers quantitative particle analysis across a dynamic size range with the specificity to distinguish between negatively buoyant protein aggregates and positively buoyant particles, such as silicone oil — a capability beyond the scope of conventional protein characterization techniques.
Archimedes counts and characterizes particles by passing a sample across micro electro-mechanical system (MEMS) sensors comprising of a cantilever which resonates with a particular frequency. Each particle which passes across the sensor causes a change in the resonant frequency, giving an accurate and precise measurement of the particle’s buoyant mass — whether positive or negative — in the sample. From this measurement, the mass, size and surface area of the particle can be accurately calculated to quickly and simply deliver measurements of sample concentration, density, volume, and polydispersity. By providing advanced insight on a molecular level, the Archimedes allows users to gain the deeper understand of their formulation required to meet the evolving needs of biopharmaceutical regulation.
Register at www.malvern.com/submicron
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance